Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 49 recruiting now full pipeline #44 of 28,707 conditions

Diabetes Mellitus: full-pipeline trial registry

49 of 210 indexed Diabetes Mellitus trials are currently recruiting.

Corpus placement: #44 of 28,707 conditions by registered trial count.

210 US clinical trials · 49 currently recruiting · #44 of 28,707 conditions by registered trial count

Diabetes Mellitus: 210 US clinical trials tracked, 49 recruiting.

Diabetes Mellitus is the subject of 210 registered US clinical trials on ClinicalTrials.gov, 49 of them currently open to new participants. 26 are in Phase 3-4 (later-stage) and 32 in Phase 1-2 (earlier-stage). The most active sponsor is Takeda, running 8 of these trials.

Enrollment posture brief

Registry condition diabetes-mellitus

OPEN 49 | RECR 23% | LATE 26 | EARLY 32 | RANK #44 | SPON 8

Nearest open-share peer: Alzheimers Disease (23% recruiting · 150 trials)

Spinal Cord Injuries53.2%Mild Cognitive Impairment48.5%Sickle Cell Disease44.4%Atrial Fibrillation29.4%Diabetes Mellitus (this)23%
Open-enrollment share among volume-matched conditions near Diabetes Mellitus

Diabetes Mellitus lists 49 open slots (23% of 210 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Diabetes Mellitus on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Diabetes Mellitus is recruiting below its size-band peers.

    49 of 210 indexed trials (23.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Diabetes Mellitus trials is spread across many organizations.

    Takeda accounts for 8 of 210 trials (3.8%). 123 distinct sponsors appear on at least one study for this condition label.

  3. Typical Diabetes Mellitus enrolment sits around 136 participants.

    Median target enrolment is 136 among the 209 trials that report a genuine target (sentinel values excluded). 86 of those (41.1%) plan for fewer than 100 participants.

  4. Diabetes Mellitus research is mostly interventional.

    175 interventional and 35 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 113Phase 219Phase 318Phase 48

Open and recent trials

210 total, page 2 of 5

ACTIVE NOT RECRUITING 5,888 participants

Cardiovascular Health Study (CHS)

National Heart, Lung, and Blood Institute (NHLBI)

NCT00005133

ACTIVE NOT RECRUITING NA 2,177 participants

Eat Well Produce Benefit for Diabetes and Food Insecurity

Duke University

NCT05896644

ACTIVE NOT RECRUITING NA 1,300 participants

SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

Medtronic Vascular

NCT05198674

ACTIVE NOT RECRUITING NA 542 participants

Dissemination of the Cardiovascular Risk Service

Korey Kennelty

NCT03660631

ACTIVE NOT RECRUITING 500 participants

Biological Sample Repository for Gastrointestinal Disorders

Pichamol Jirapinyo, MD, MPH

NCT05874726

ACTIVE NOT RECRUITING NA 347 participants

Eat, Move, Live Program for the Reduction of Cancer and Chronic Disease Risk in Underserved Communities

City of Hope Medical Center

NCT05414396

ACTIVE NOT RECRUITING Phase 4 255 participants

Oral Anti Diabetic Agents in the Hospital

Emory University

NCT04416269

ACTIVE NOT RECRUITING NA 185 participants

Texting for Diabetes

St. Louis University

NCT03025984

ACTIVE NOT RECRUITING NA 122 participants

The REST Study for CGM Use in Older Adults With Insulin-treated Diabetes

Joslin Diabetes Center

NCT05337826

ACTIVE NOT RECRUITING Phase 4 121 participants

People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT03520660

ACTIVE NOT RECRUITING NA 120 participants

Black Girls Move Physical Activity and Improving Dietary Intake Among Black Adolescent Daughters

Rush University Medical Center

NCT05433415

ACTIVE NOT RECRUITING 75 participants

Glucose Metabolism in Sickle Cell Disease

University of Illinois at Chicago

NCT02922296

ACTIVE NOT RECRUITING NA 48 participants

A Sugar-Sweetened Beverage Reduction Intervention for Native American Men

Roswell Park Cancer Institute

NCT06029517

ACTIVE NOT RECRUITING NA 40 participants

Continuous Glucose Monitoring of Hospitalized Patients With Diabetes

Baylor Research Institute

NCT04230694

ACTIVE NOT RECRUITING NA 40 participants

Glycemic Emergency Management (GEM); An App for Rapid Response to Hypoglycemic and Hyperglycemic Situations

Marshall University

NCT02336217

ACTIVE NOT RECRUITING NA 37 participants

Food is Medicine vs Lifestyle Medicine For Cardiovascular Kidney Metabolic (CKM) Syndrome

Rutgers, The State University of New Jersey

NCT06461273

ACTIVE NOT RECRUITING NA 35 participants

Study of a Primary Care Hypoglycemia Prevention Program

Johns Hopkins University

NCT06353217

ACTIVE NOT RECRUITING NA 28 participants

Community Health Workers in Pediatric Patients With Newly Diagnosed Type 1 Diabetes

Children's Hospital of Philadelphia

NCT04238949

ACTIVE NOT RECRUITING NA 25 participants

Plant-based Diet for Kidney Transplant Recipients

George Washington University

NCT06186843

ACTIVE NOT RECRUITING NA 20 participants

Enhancing Mental and Physical Health of Women Veterans

VA Office of Research and Development

NCT05050266

ACTIVE NOT RECRUITING Phase 1 17 participants

Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen

City of Hope Medical Center

NCT00706420

COMPLETED 57,073 participants

Evaluation of VLER-Indiana Health Information Exchange Demonstration Project

VA Office of Research and Development

NCT01446705

COMPLETED 28,813 participants

Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program

Brigham and Women's Hospital

NCT03326206

COMPLETED NA 13,155 participants

Evaluation of a Dashboard for Diabetes Care Integrated With the Electronic Health Record

University of Utah

NCT03826290

COMPLETED Phase 3 10,251 participants

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

National Heart, Lung, and Blood Institute (NHLBI)

NCT00000620

COMPLETED NA 9,501 participants

Personalized Patient Data and Behavioral Nudges to Improve Adherence to Chronic Cardiovascular Medications

University of Colorado, Denver

NCT03973931

COMPLETED NA 7,052 participants

Blood Glucose Monitoring in Electronic Health Records

Inova Health Care Services

NCT03542487

COMPLETED 6,000 participants

Improving Diabetes in Primary Care (IMPACT)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT00108927

COMPLETED NA 5,000 participants

Clinical Decision Support for Medication Management and Adherence

Duke University

NCT00979225

COMPLETED NA 4,994 participants

Glucose to Goal: A Model to Support Diabetes Management in Primary Care

University of Pittsburgh

NCT02715934

COMPLETED NA 3,000 participants

Improving Quality With Outpatient Decision Support

Agency for Healthcare Research and Quality (AHRQ)

NCT00225628

COMPLETED NA 2,000 participants

Study to Evaluate the Effectiveness of a Program Developed to Improve Eye Care for Veterans With Diabetes

US Department of Veterans Affairs

NCT00119535

COMPLETED NA 1,665 participants

Randomized Trial of Telemedicine for Diabetes Care

Columbia University

NCT00271739

COMPLETED NA 1,485 participants

Diabetes-Depression Care-management Adoption Trial

University of Southern California

NCT01781013

COMPLETED Phase 3 1,100 participants

A Clinical Trial Assessing the Impact of the Availability of Inhaled Insulin on Glucose Control

Pfizer

NCT00134147

COMPLETED Phase 3 803 participants

Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus

Takeda

NCT00432276

COMPLETED NA 773 participants

Integrating Community Health Workers to Improve Diabetes Prevention

NYU Langone Health

NCT03006666

COMPLETED 750 participants

CV Disease in Adolescents With Type 2 Diabetes

Children's Hospital Medical Center, Cincinnati

NCT00114998

COMPLETED Phase 3 719 participants

Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia

Takeda

NCT00331487

COMPLETED Phase 2 699 participants

Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves

Tris Pharma

NCT01939366

COMPLETED Phase 3 695 participants

Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo

AstraZeneca

NCT02229396

COMPLETED NA 650 participants

Meals MATTER: A Trial of Medically Tailored Meals 2 Weeks vs. 4 Weeks Post Hospital Discharge

Kaiser Permanente

NCT04351880

COMPLETED 628 participants

Evaluation of the Analytical Performance of ALLEGRO™ Instrument

Nova Biomedical

NCT04096313

COMPLETED 621 participants

Screening for Patients Needing Kidney, Kidney-Pancreas, or Islet-Cell Transplant

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT00001859

COMPLETED Phase 3 600 participants

Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.

Takeda

NCT00727857

COMPLETED NA 550 participants

Effect of Care Management on Diabetes Outcomes

Minneapolis Veterans Affairs Medical Center

NCT00569556

COMPLETED NA 550 participants

Multidisciplinary Inpatient Palliative Care Intervention

Kaiser Permanente

NCT00325611

COMPLETED Phase 3 547 participants

Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus

Takeda

NCT00225277

COMPLETED NA 543 participants

User Evaluation of the Invasive Component of the CNOGA TensorTip COMBO GLUCOMETER (CoG)

Sciema UG

NCT03870971

COMPLETED Phase 3 527 participants

Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus

Takeda

NCT00286442

← Previous Page 2 of 5 Next →

Phase Distribution

PhaseTrial count
Phase 1 13
Phase 2 19
Phase 3 18
Phase 4 8

Named interventions

Most-linked intervention names on Diabetes Mellitus records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
9 trials
Pioglitazone Drug
5 trials
Metformin Drug
5 trials
THR-149 dose level 3 Drug
2 trials
THR-149 dose level 2 Drug
2 trials
THR-149 dose level 1 Drug
2 trials
Apollo Blood Glucose Monitoring System Device
2 trials
Lispro Drug
2 trials

US sites by state

Facility locations filed on Diabetes Mellitus trials. A trial with sites in several states counts in each.

California 46 trials
Florida 30 trials
Arizona 24 trials
Massachusetts 22 trials
Colorado 22 trials
Maryland 21 trials
Pennsylvania 20 trials
New York 20 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Diabetes Mellitus page

210 registered trials, 49 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 49 Diabetes Mellitus trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Takeda sponsors the most Diabetes Mellitus trials on record, review their full trial history before evaluating a specific study. See Takeda's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diabetes Mellitus condition card totals 210 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.